Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed and Refractory CLL/SLL and B-PLL
NCT01589302Phase 2Active, not recruiting
- Start
- May 2012
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL). Started May 2012; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT01589302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589302.